<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295018</url>
  </required_header>
  <id_info>
    <org_study_id>0203-007</org_study_id>
    <nct_id>NCT04295018</nct_id>
  </id_info>
  <brief_title>A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma</brief_title>
  <official_title>A Phase # Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088&#xD;
      in relapsed or refractory multiple myeloma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Apheresis, Baseline,&#xD;
      Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and&#xD;
      Follow-up Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of adverse events (TEAEs) within 30 days after intravenous infusion of C-CAR088</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>ORR(including sCR / CR / VGPR / PR, based on IMWG 2016 efficacy evaluation criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months#12 months</time_frame>
    <description>PFS(based on IMWG 2016 efficacy evaluation criteria)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>C-CAR088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-CAR088</intervention_name>
    <description>Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.</description>
    <arm_group_label>C-CAR088</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-75 years old, male or female;&#xD;
&#xD;
          2. The patient volunteered to participate in the study, and he or his legal guardian&#xD;
             signed the Informed Consent;&#xD;
&#xD;
          3. Patients with a clear diagnosis of relapsed or refractory multiple myeloma&#xD;
&#xD;
          4. The patient have one or more measurable multiple myeloma lesion, must include one of&#xD;
             the following conditions:&#xD;
&#xD;
               -  Serum M protein≥1.0 g/dL(10g/L)&#xD;
&#xD;
               -  Urine M protein≥200 mg/24h&#xD;
&#xD;
               -  Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥10mg /&#xD;
                  dL&#xD;
&#xD;
          5. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological&#xD;
             examination;&#xD;
&#xD;
          6. At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy.&#xD;
&#xD;
          7. ECOG scores 0 - 1;&#xD;
&#xD;
          8. Good cardiac and pulmonary organ function;&#xD;
&#xD;
          9. Expected survival time &gt; 12 weeks;.&#xD;
&#xD;
         10. Female subjects of childbearing age must have a negative urine / blood pregnancy test&#xD;
             within 7 days before cell therapy and not be in lactation; female or male subjects of&#xD;
             childbearing age need to take effective contraception throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of allergy to cellular products;&#xD;
&#xD;
          2. Laboratory testing occurs when: including but not limited to, serum total bilirubin&#xD;
             ≥1.5mg / dl; serum ALT or AST is 2.5 times higher than the upper limit of normal&#xD;
             value; serum creatinine ≥2.0mg / dl; hemoglobin &lt;80g / L; absolute neutrophil count&#xD;
             &lt;1000 / mm3 or dependent on GCSF or Other growth factors can maintain the centriole&#xD;
             count ≥1000 / mm²; platelet count &lt;50000 / mm³ or the above level can be maintained&#xD;
             due to platelet transfusion;&#xD;
&#xD;
          3. Presence of clinically significant cardiovascular disease, such as uncontrolled or&#xD;
             symptomatic arrhythmias, congestive heart failure, or any heart function Grade 3&#xD;
             (moderate) or Grade 4 (severe) heart disease (according to the New York Heart&#xD;
             Association Function Classification method: NYHA); patients with a history of&#xD;
             myocardial infarction, cardiac angioplasty or stent implantation, unstable angina&#xD;
             pectoris or other clinically significant heart disease within 12 months before&#xD;
             enrollment;&#xD;
&#xD;
          4. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral&#xD;
             ischemia or hemorrhagic disease;&#xD;
&#xD;
          5. Need to use any anticoagulant (except aspirin);&#xD;
&#xD;
          6. Patients requiring urgent treatment due to tumor progression or spinal cord&#xD;
             compression;&#xD;
&#xD;
          7. Patients with CNS metastasis or symptoms of CNS involvement;&#xD;
&#xD;
          8. After allogeneic hematopoietic stem cell transplantation;&#xD;
&#xD;
          9. Plasma cell leukemia;&#xD;
&#xD;
         10. Patients with autoimmune diseases, immunodeficiency, or other immunosuppressive&#xD;
             agents;&#xD;
&#xD;
         11. Uncontrolled active infection;&#xD;
&#xD;
         12. Have used any CAR T cell products or other genetically modified T cell therapy before;&#xD;
&#xD;
         13. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as&#xD;
             acquired, congenital immune deficiency diseases, including but not limited to HIV&#xD;
             infected persons;&#xD;
&#xD;
         14. Have a history of alcoholism, drug addiction and mental illness;&#xD;
&#xD;
         15. Participated in any other clinical trial within 1 months;&#xD;
&#xD;
         16. The investigators believe that there are other circumstances that are not suitable for&#xD;
             the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daobin Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daobin Zhou, PhD&amp;MD</last_name>
    <phone>010-69155020</phone>
    <email>zhoudb@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Zhang</last_name>
    <phone>010-69155660</phone>
    <email>pumczhanglu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daobin Zhou, PhD&amp;MD</last_name>
      <phone>010-69155020</phone>
      <email>zhoudb@pumch.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lu Zhang</last_name>
      <phone>010-69155660</phone>
      <email>pumczhanglu@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

